Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Endocannabinoids, cannabinoid receptors and inflammatory stress: an interview with Dr. Pál [corrected] Pacher. Interviewed by Helene F. Rosenberg.

Pacher PA.

J Leukoc Biol. 2007 Dec;82(6):1390-2. No abstract available. Erratum in: J Leukoc Biol. 2008 Feb;83(2):438.

PMID:
18040082
2.

Cannabinoids, endocannabinoids, and cancer.

Hermanson DJ, Marnett LJ.

Cancer Metastasis Rev. 2011 Dec;30(3-4):599-612. doi: 10.1007/s10555-011-9318-8. Review.

3.

From endocannabinoid profiling to 'endocannabinoid therapeutics'.

Ligresti A, Petrosino S, Di Marzo V.

Curr Opin Chem Biol. 2009 Jun;13(3):321-31. doi: 10.1016/j.cbpa.2009.04.615. Epub 2009 Jun 3. Review.

PMID:
19497779
4.

Endocannabinoid overactivity and intestinal inflammation.

Di Marzo V, Izzo AA.

Gut. 2006 Oct;55(10):1373-6.

5.

Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases.

Pacher P, Gao B.

Am J Physiol Gastrointest Liver Physiol. 2008 Apr;294(4):G850-4. doi: 10.1152/ajpgi.00523.2007. Epub 2008 Jan 31. Review.

6.

The enigmatic pharmacology of GPR55.

Ross RA.

Trends Pharmacol Sci. 2009 Mar;30(3):156-63. doi: 10.1016/j.tips.2008.12.004. Epub 2009 Feb 21. Review.

PMID:
19233486
7.

Cannabinoid system in neurodegeneration: new perspectives in Alzheimer's disease.

Campillo NE, Páez JA.

Mini Rev Med Chem. 2009 May;9(5):539-59. Review.

PMID:
19456285
8.

Role of cannabinoids and endocannabinoids in cerebral ischemia.

Hillard CJ.

Curr Pharm Des. 2008;14(23):2347-61. Review.

9.

Therapeutic opportunities through modulation of the endocannabinoid system.

Makriyannis A, Mechoulam R, Piomelli D.

Neuropharmacology. 2005 Jun;48(8):1068-71. No abstract available.

PMID:
15885714
11.

Cannabis and endocannabinoids: 'the old man and the teenagers'.

Lambert DM.

Chem Biodivers. 2007 Aug;4(8):1609-13. No abstract available.

PMID:
17712810
12.

[Functional organization ant therapeutic potential of the endogenous cannabinoid system].

Churiukanov MV, Churiukanov VV.

Eksp Klin Farmakol. 2004 Mar-Apr;67(2):70-8. Review. Russian. No abstract available.

PMID:
15188768
13.

Endocannabinoid mechanisms of pain modulation.

Hohmann AG, Suplita RL 2nd.

AAPS J. 2006 Nov 17;8(4):E693-708. Review.

14.

The complications of promiscuity: endocannabinoid action and metabolism.

Alexander SP, Kendall DA.

Br J Pharmacol. 2007 Nov;152(5):602-23. Epub 2007 Sep 17. Review.

15.

Basic neuroanatomy and neuropharmacology of cannabinoids.

Breivogel CS, Sim-Selley LJ.

Int Rev Psychiatry. 2009 Apr;21(2):113-21. doi: 10.1080/09540260902782760. Review.

PMID:
19367505
16.

Signaling via CNS cannabinoid receptors.

Mackie K.

Mol Cell Endocrinol. 2008 Apr 16;286(1-2 Suppl 1):S60-5. doi: 10.1016/j.mce.2008.01.022. Epub 2008 Feb 6. Review.

17.

Cannabis, cannabinoids and reproduction.

Park B, McPartland JM, Glass M.

Prostaglandins Leukot Essent Fatty Acids. 2004 Feb;70(2):189-97. Review.

PMID:
14683692
18.

Inhibitors of endocannabinoid degradation: potential therapeutics for neurological disorders.

Wendeler M, Kolter T.

Angew Chem Int Ed Engl. 2003 Jul 7;42(26):2938-41. No abstract available.

PMID:
12851943
19.

Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.

Pacher P, Haskó G.

Br J Pharmacol. 2008 Jan;153(2):252-62. Epub 2007 Nov 19. Review.

20.

The endocannabinoid system: potential for reducing cardiometabolic risk.

Ginsberg HN, Woods SC.

Obesity (Silver Spring). 2009 Oct;17(10):1821-9. doi: 10.1038/oby.2009.107. Epub 2009 Apr 16. Review. No abstract available.

Supplemental Content

Support Center